GAP

Solutions for a sanitary shield against avian and pandemic influenza

GAP est accrédité par Lyonbiopôle

Identity card

Global budget: 17125 k€

Public funding: 3669 k€

Public funders: Fonds Unique Interministériel (FUI) – DGCIS/Oséo

Call for projects: FUI (FUI AAP0)

Year start: 2005

Completed project (2009-12)


Accredited by the French competitiveness cluster Lyonbiopôle


Strategic business area: Animal Medicines, In vitro Diagnostic, Medical Technologies

Application fields: Infectious diseases

Technological approaches / Keywords: Biochips, Functional Screening / Drug discovery, Vector vaccine

Stage of development at the beginning of the project: Basic research, Discovery

Abstract

New influenza vaccines based on vector and inactivated vaccines were tested in chickens, swine and cats. The immunogenicity of prime-boost regimen using both types of vaccines was found to be higher. Improvements in influenza vaccine production, reverse genetics, in vitro reassortments were made. Nasba-based diagnostic test aiming to detect H5 and N1 was simplified and a micro array aiming to characterize diagnostic influenza samples was designed. The interactomes of proteins from different influenza strains were established and a new family of interacting cellular proteins was identified.   


Objectives

The main objectives of the project concern three topics:  - Vaccines: To evaluate the immunogenicity of current vaccines in different species against recent emerging influenza strains and to develop new types of vaccines and related production systems in order to immunize more easily and rapidly the target human and/or animal population against emerging strains of influenza virus. - Diagnosis: To develop and evaluate new diagnostic tools. - Interactome: To identify and study interactions between viral and cellular proteins.


Innovative assets
Highlights
Actual results
Perspectives

Innovative assets

A new promising vector based on a paramyxovirus was developed for poultry. The prime-boost regimen using  both vector vaccines and classical inactivated vaccine was found to be superior to either vaccine used once or twice, especially in birds with maternally-derived antibodies. In cats and pigs, poxvirus vectors were found to be efficacious against H5 challenges. Identification of cellular proteins interacting with influenza proteins led to the identification of new targets for viral therapeutics. A new technology able to induce production and secretion of proteins of interest was developed.

En poursuivant votre navigation sur notre site, vous acceptez l'utilisation des cookies et la collecte de vos données et informations personnelles par Lyonbiopôle, dans les finalités de mesurer le trafic sur le site Web, de fournir des statistiques et de vous proposer des contenus adaptés à vos centres d’intérets. Pour exercer vos droits d'accès, de rectification, d'opposition, de suppression et de portabilité, conformément au règlement général sur la protection des données (UE n°2016/679), vous etes informés que vous pouvez envoyer votre demande à dpo@lyonbiopole.com. Plus de détails sont disponibles en cliquant ici J'accepte